Niranjan Venugopal1, 2, Lawrence Ryner3, Keith Nakonechny2, Boyd McCurdy2
1Physics and Astronomy, University of Manitoba, Winnipeg, Manitoba, Canada; 2Medical Physics, CancerCare Manitoba, Winnipeg, Manitoba, Canada; 3National Research Council Institute for Biodiagnostics
Using intensity modulated radiation therapy (IMRT), we can now accurately deliver radiation doses to dominant intraprostatic lesions as identified by 1H-MRSI. Using a modified tumour control probability (TCP) formalism, which includes the 1H-MRSI data, we determine the optimal dose distribution that would enable equivalent control of the prostate cancer by escalating the dose to the localized DIL. The TCP and normal tissue complication probability (NTCP) for both plans were calculated, and compared. The result of this study indicates that optimizing the dose to the prostate according to 1H-MRSI information is possible, and that it can be used to logically derive new prescription doses leading to improved TCP.